Laboratory medicine plays an important role in the diagnosis and therapy of oncological diseases and opens a new diagnostic window by the analysis of cell-free circulating tumor DNA (ctDNA).
Liquid profiling or liquid biopsy allows minimally invasive analysis of tumor-associated genetic alterations directly from the patient’s blood and can thus be used to longitudinally assess tumor evolution by molecular genetics and to individually stratify the therapeutic regimen. In addition to preanalytical factors, the use of highly sensitive analytical methods is critical for reliable results.
The Committee on Molecular Diagnostics (C-MD) of the IFCC would now like to ask all colleagues in clinical laboratories what the current status of diagnostics is. We want to understand how laboratories are handling diagnostics using this diagnostic approach.
The survey will take about 10 minutes of your time and you can choose between a Spanish and an English version.
We would greatly appreciate your participation in the survey by July 1.
Please complete the survey and distribute it to all clinical colleagues in your country who perform ctDNA molecular genetic analysis.